Many stakeholders believe innovation only leads to generating new molecules, but innovation can also come from other areas such as focusing on improving present molecules which are no longer protected by patent.
There is significant untapped potential in Europe to optimise existing therapies and value added medicines represent an opportunity for patients, healthcare providers, payers, industry and the healthcare systems in general.
Come and join us for the first Value Added Medicines Conference in Brussels to learn more about value added medicines and to discuss the current environment, challenges and opportunities in Europe.
Keynote Speeches
Tackling wasteful spending on health
Main topics
Incremental innovation on known molecules – Necessity to address all patient needs?
Value added medicines – How to capture their value for society
The target audience is policy makers, industry, academics and other stakeholders involved.
The discussion will be on repurposing medicines.
More information and link to registration can be found here.
The conference "European innovation partnership on active and healthy ageing: from plan to action" will be opened by Neelie Kroes, the European Commissioner for digital agenda and John Dalli, the European Commissioner for health and consumer policy.